Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.81 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.81 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.81 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.81 |
| ▸ | ABL1 | P00519 | 1/20 | 0.81 |
| ▸ | PIM1 | P11309 | 1/20 | 0.81 |
| ▸ | PRKACA | P17612 | 1/20 | 0.81 |
| ▸ | LTK | P29376 | 1/20 | 0.81 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.81 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.81 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.81 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.81 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.81 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.81 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.81 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.81 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941271 | 0.90 | EGFR (1.00) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL8920 | 0.90 | EGFR (1.00) | EGFRABCG2ERBB2AURKBCLK4 | |
| Hydrochloric Acid SCHEMBL8808235 | 0.88 | EGFR (0.90) | EGFRABCG2ERBB2AURKBCLK4 | |
| Hydrochloric Acid SCHEMBL20856873 | 0.88 | EGFR (0.96) | EGFRABCG2ERBB2AURKBCLK4 | |
| Hydrochloric Acid SCHEMBL29394578 | 0.88 | EGFR (0.96) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL15051337 | 0.84 | BRAF (0.84) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL14027230 | 0.83 | EGFR (0.75) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL5569016 | 0.83 | EGFR (0.75) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL29894633 | 0.83 | ABCG2 (1.00) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL5569041 | 0.83 | EGFR (0.75) | EGFRABCG2ERBB2AURKBCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885ABCG2 311/4885ERBB2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.